Get started
Author

Tokiko Asami

Observed name: Asami, Tokiko
ORCID: 0000-0001-6783-4091
Observed ORCID: 0000-0001-6783-4091
OpenAlex ID: A5081638860
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis
2018 · Wataru Kawahata, Tokiko Asami, et al. · Journal of Medicinal Chemistry · 36
Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors
2017 · Takayuki Irie, Tokiko Asami, et al. · European Journal of Medicinal Chemistry · 30
Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton’s Tyrosine Kinase
2021 · Wataru Kawahata, Tokiko Asami, et al. · Journal of Medicinal Chemistry · 29
A novel meta‐cleavage dioxygenase that cleaves a carboxyl‐group‐substituted 2‐aminophenol: Purification and characterization of 4‐amino‐3‐hydroxybenzoate 2,3‐dioxygenase from Bordetella sp. strain 10d
2002 · Shinji Takenaka, Tokiko Asami, et al. · European Journal of Biochemistry · 17
PDF
Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors
2017 · Wataru Kawahata, Tokiko Asami, et al. · Bioorganic & Medicinal Chemistry Letters · 15
Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers
2021 · Takayuki Irie, Tokiko Asami, et al. · Journal of Medicinal Chemistry · 12
Abstract B152: CB1763, a highly selective, novel non-covalent BTK inhibitor, targeting ibrutinib-resistant BTK C481S mutant
2018 · Tokiko Asami, Wataru Kawahata, et al. · Molecular Cancer Therapeutics · 7
TR-FRET binding assay targeting unactivated form of Bruton’s tyrosine kinase
2015 · Tokiko Asami, Wataru Kawahata, et al. · Bioorganic & Medicinal Chemistry Letters · 6
‘Turn On/Off’ fluorescence probe for the screening of unactivated Bruton’s tyrosine kinase
2015 · Wataru Kawahata, Tokiko Asami, et al. · Bioorganic & Medicinal Chemistry Letters · 4
Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers
2024 · Natalia Timofeeva, Breana Herrera, et al. · Blood · 2
Abstract C93: The design and synthesis of a novel fluorogenic probe targeting inactive forms of Burton's tyrosine kinase for high-throughput binding assay.
2011 · Wataru Kawahata, Tokiko Asami, et al. · Molecular Cancer Therapeutics · 1
Abstract C94: A novel binding assay to identify inhibitors that bind to inactive forms of Bruton's tyrosine kinase based on fluorescence resonance energy transfer.
2011 · Tokiko Asami, Wataru Kawahata, et al. · Molecular Cancer Therapeutics · 1
Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations
2026 · Natalia Timofeeva, Breana Herrera, et al. · Blood Cancer Journal
Characterization and Preclinical Evaluation of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Chronic Lymphocytic Leukemia
2023 · Shady I. Tantawy, Natalia Timofeeva, et al. · Blood
PDF
Abstract 1400: AS-1763: a highly potent, noncovalent and next generation BTK inhibitor for the treatment of patients with B-cell malignancies having C481S mutation in BTK
2022 · Wataru Kawahata, Tokiko Asami, et al. · Cancer Research
CCDC 2083520: Experimental Crystal Structure Determination
2021 · Irie, Takayuki, Asami, Tokiko, et al. · The Cambridge Structural Database
Abstract 3232: Development of novel Btk inhibitor, CB988 targering ibrutinib-resistant Btk C481S mutant
2017 · Wataru Kawahata, Tokiko Asami, et al. · Cancer Research
Abstract A180: Discovery of furanone derivatives as novel Cdc7 inhibitors with anti-tumor activity
2015 · Takayuki Irie, Tokiko Asami, et al. · Molecular Cancer Therapeutics
Works count: 18
Citation count: 160
H-index: 7
I10-index: 6
Year
Topic
Type